Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$27,000.00

Mapping Molecular and Behavioural Impacts of SETBP1 Deficiency in Zebrafish

FY 2024-25

Summary
SETBP1 haploinsufficiency disorder (SETBP1-HD) is a rare human genetic disorder (<250 cases worldwide) that affects development —particularly neurodevelopment. It is caused by a loss of function (LoF) in in the SETBP1 region, which results in insufficient production of SET binding protein 1. When SETBP1 expression is low, key developmental genes are underexpressed, leading to developmental delay phenotypes including autism spectrum disorder, attention-deficit/hyperactivity disorder, and reduced muscle tone. The aim of this study is to leverage a mutant line of SETBP1-LoF zebrafish to discover disease pathways underlying SETBP1-HD and identify potential therapeutics. This will be achieved through three research objectives. Firstly, behavioural symptoms of SETBP1-LoF will be characterized via high-throughput behavioural tracking. Secondly, pathways underlying reduced muscle tone in SETBP1-LoF will be determined by fluorescent imaging of motor neuron, fast twitch, and slow twitch muscle activity. Thirdly, potential therapeutic targets for SETBP1-HD will be identified and screened. In collaboration with Dr. Valerie Tornini (UCLA), we will computationally compare our SETBP1-LoF behavioural phenotypes to a library of behavioural responses to known FDA-approved drugs, to narrow in on potential underlying pathways. Then, we will empirically test the ability of therapeutics to rescue behavioural and muscular phenotypes via high-throughput drug screening. This will narrow down therapeutic candidates for mammalian trials and will provide insight regarding the molecular underpinnings of disease-linked variants, including Schinzel-Giedion syndrome (another rare genetic disorder) and leukemia.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
563435
Name
Ullrich Katherine M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Mapping Molecular and Behavioural Impacts of SETBP1 Deficiency in Zebrafish
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Behaviour; Drug Discovery; Fish; Muscle; Pathology; Physiology; Rare Disease
Abstract
SETBP1 haploinsufficiency disorder (SETBP1-HD) is a rare human genetic disorder (<250 cases worldwide) that affects development —particularly neurodevelopment. It is caused by a loss of function (LoF) in in the SETBP1 region, which results in insufficient production of SET binding protein 1. When SETBP1 expression is low, key developmental genes are underexpressed, leading to developmental delay phenotypes including autism spectrum disorder, attention-deficit/hyperactivity disorder, and reduced muscle tone. The aim of this study is to leverage a mutant line of SETBP1-LoF zebrafish to discover disease pathways underlying SETBP1-HD and identify potential therapeutics. This will be achieved through three research objectives. Firstly, behavioural symptoms of SETBP1-LoF will be characterized via high-throughput behavioural tracking. Secondly, pathways underlying reduced muscle tone in SETBP1-LoF will be determined by fluorescent imaging of motor neuron, fast twitch, and slow twitch muscle activity. Thirdly, potential therapeutic targets for SETBP1-HD will be identified and screened. In collaboration with Dr. Valerie Tornini (UCLA), we will computationally compare our SETBP1-LoF behavioural phenotypes to a library of behavioural responses to known FDA-approved drugs, to narrow in on potential underlying pathways. Then, we will empirically test the ability of therapeutics to rescue behavioural and muscular phenotypes via high-throughput drug screening. This will narrow down therapeutic candidates for mammalian trials and will provide insight regarding the molecular underpinnings of disease-linked variants, including Schinzel-Giedion syndrome (another rare genetic disorder) and leukemia.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ullrich, Katherine M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~